Medication info
Gluripitin Duo XR Tablets 5/1000 mg (Linagliptin, Metformin Hydrochloride)

Gluripitin Duo XR Tablets 5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Micronized›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Samchundang Pharmaceutical Co., Ltd.
Appearance
White oval extended-release film-coated tablets
Packaging
30 tablets per bottle
Approval status
Active

MFDS item code 202400662 · Approved 2024.03.26 · Insurance code 651206130

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5 mg and metformin hydrochloride extended-release 2000 mg. This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 5/1000 mg extended-release tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000 mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5 mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored, and the dose should be adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should correspond to the current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Samchundang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This drug is used to assist patients with type 2 diabetes who must use both linagliptin and metformin in controlling their blood sugar. It is more effective when combined with dietary adjustments and exercise therapy, helping to manage blood sugar levels reliably. Thus, it serves as a good adjunct in the treatment of type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5 mg and metformin hydrochloride extended-release 2000 mg. This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 5/1000 mg extended-release tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000 mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5 mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored, and the dose should be adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should correspond to the current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This drug helps in controlling blood sugar levels. However, it should be noted that a rare but serious side effect called lactic acidosis, which involves excessive accumulation of lactic acid in the body, may occur, requiring caution. Especially in patients with poor kidney function or liver problems, serious infections, dehydration, or acute heart disease, this drug should not be used. Additionally, individuals with allergies to any of the ingredients in this drug should avoid taking it. This drug may cause hypoglycemia, so blood sugar levels should be monitored frequently, especially when used with other hypoglycemic agents or insulin. Excessive exercise, skipping meals, or alcohol consumption can also increase the risk of hypoglycemia, so caution is advised. Elderly patients with reduced kidney function or those with kidney disease must have regular kidney function tests and should discuss with their physician whether or not to take this drug. Adverse reactions such as acute pancreatitis or skin blistering, similar to bullous pemphigoid, may occur, so if sudden abdominal pain or skin changes occur during treatment, inform your doctor immediately. This drug should be swallowed whole and not chewed, crushed, or split, and the tablet coating may appear in bowel movements, but this is normal. Women who are pregnant or breastfeeding should avoid using this drug, and those planning to become pregnant should consult their doctor. Additionally, since this drug may interact with several medications, be sure to inform medical personnel if you are taking any other medications. If any sudden symptoms or adverse reactions occur during treatment with this drug, seek medical attention immediately.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • nasopharyngitis
  • hypersensitivity reactions
  • angioedema
  • urticaria
  • lactic acidosis
  • abnormal vitamin B12 absorption test
  • hypoglycemic episodes
  • taste disturbance
Show 113 more
  • cough
  • reduced appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcers
  • abnormal liver function tests
  • hepatitis
  • itching
  • erythema
  • rash
  • similar to pemphigus
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer-type dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • stomach cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • dizziness
  • kidney transplant failure
  • anxiety
  • mood disorders
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • nausea
  • gastroesophageal reflux disease
  • dizziness
  • sensory impairment
  • chest discomfort
  • weakness
  • pain
  • nosebleed
  • oropharyngeal pain
  • voice disturbance
  • nasal bleeding
  • benign prostatic hyperplasia
  • male pattern baldness
  • hyperhidrosis
  • dermatitis
  • anxiety
  • confusion
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This drug may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the drug's effectiveness.

Appearance and packaging

Appearance

White oval extended-release film-coated tablets

Package unit

30 tablets per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.